ALTO-100
Major Depressive Disorder (MDD)
Phase 2aCompleted
Key Facts
About Alto Neuroscience
Alto Neuroscience is a precision psychiatry company leveraging a proprietary AI-driven biomarker platform to develop targeted therapies for major depressive disorder, bipolar depression, and schizophrenia. Founded in 2019 and built on 15 years of foundational neurobiology research, the company has rapidly advanced a multi-asset clinical pipeline. Its core strategy is to use objective measures of brain function to identify patient subpopulations most likely to respond to its novel drug candidates, thereby increasing clinical success rates and commercial potential.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |
| Major Depressive Disorder Program | Actipulse Neuroscience | Phase 3 |
| Flow tDCS Headset & App | Flow Neuroscience | Approved |